QSAR Study on a Series of Protein Tyrosine Phosphatase 1B Inhibitors

Overview

Journal Int J Biomed Sci

Specialty General Medicine

Date 2013 May 16

PMID 23675100

Authors

Rajendra S Mehta

Hetal R Prajapati

Dinesh V Thakkar

Pathik S Brahmkshatriya

Affiliations

Soon will be listed here.

Abstract

As a therapeutic target, protein tyrosine phosphatase 1B (PTP1B) has received considerable attention for the treatment of diabetes mellitus. A QSAR study using substituted monocyclic and polycyclic thiophene derivatives, recently reported as potent PTP1B inhibitors, was carried out. More than 60 physicochemical descriptors were calculated which underwent rational selection before their use in derivation of QSAR models. Statistically significant equations were generated using multiple linear regression analysis. External validation of the derived models with test set compounds proved good predictability of the models. Interpretation of the results revealed lipophilicity as a key regulatory feature which affects PTP1B inhibition along with several electronic and steric parameters. The study provides an important platform upon which novel rationally designed molecules can be synthesized with cautious optimism.

References

Johnson T, Ermolieff J, Jirousek M . Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov. 2002; 1(9):696-709. DOI: 10.1038/nrd895. View

Klaman L, Boss O, Peroni O, Kim J, Martino J, Zabolotny J . Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol. 2000; 20(15):5479-89. PMC: 85999. DOI: 10.1128/MCB.20.15.5479-5489.2000. View

Goldstein B, White M, Harbeck M . Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J Biol Chem. 2000; 275(6):4283-9. DOI: 10.1074/jbc.275.6.4283. View

Byon J, Kusari A, Kusari J . Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol Cell Biochem. 1998; 182(1-2):101-8. View

Moretto A, Kirincich S, Xu W, Smith M, Wan Z, Wilson D . Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem. 2005; 14(7):2162-77. DOI: 10.1016/j.bmc.2005.11.005. View

Wan Z, Follows B, Kirincich S, Wilson D, Binnun E, Xu W . Probing acid replacements of thiophene PTP1B inhibitors. Bioorg Med Chem Lett. 2007; 17(10):2913-20. DOI: 10.1016/j.bmcl.2007.02.043. View

Wan Z, Lee J, Xu W, Erbe D, Joseph-McCarthy D, Follows B . Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: capturing interactions with Asp48. Bioorg Med Chem Lett. 2006; 16(18):4941-5. DOI: 10.1016/j.bmcl.2006.06.051. View

Golbraikh A, Tropsha A . Beware of q2!. J Mol Graph Model. 2002; 20(4):269-76. DOI: 10.1016/s1093-3263(01)00123-1. View

Zimmet P, Alberti K, Shaw J . Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782-7. DOI: 10.1038/414782a. View

10.

Saltiel A, Kahn C . Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001; 414(6865):799-806. DOI: 10.1038/414799a. View

11.

Obici S, Feng Z, Karkanias G, Baskin D, Rossetti L . Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci. 2002; 5(6):566-72. DOI: 10.1038/nn0602-861. View

12.

Yue E, Wayland B, Douty B, Crawley M, McLaughlin E, Takvorian A . Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: synthesis and structure-activity relationships of a peptide scaffold. Bioorg Med Chem. 2006; 14(17):5833-49. DOI: 10.1016/j.bmc.2006.05.032. View

13.

DeFronzo R, Bonadonna R, Ferrannini E . Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992; 15(3):318-68. DOI: 10.2337/diacare.15.3.318. View

14.

Black E, Breed J, Breeze A, Embrey K, Garcia R, Gero T . Structure-based design of protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett. 2005; 15(10):2503-7. DOI: 10.1016/j.bmcl.2005.03.068. View

15.

Tonks N, Diltz C, FISCHER E . Purification of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem. 1988; 263(14):6722-30. View

16.

Cho S, Baek J, Han S, Kang S, Ha J, Ahn J . PTP-1B inhibitors: cyclopenta[d][1,2]-oxazine derivatives. Bioorg Med Chem Lett. 2005; 16(3):499-502. DOI: 10.1016/j.bmcl.2005.10.062. View

17.

Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy A . Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999; 283(5407):1544-8. DOI: 10.1126/science.283.5407.1544. View

18.

Sparks R, Polam P, Zhu W, Crawley M, Takvorian A, Mclaughlin E . Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett. 2006; 17(3):736-40. DOI: 10.1016/j.bmcl.2006.10.079. View

19.

Zhao H, Liu G, Xin Z, Serby M, Pei Z, Szczepankiewicz B . Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Bioorg Med Chem Lett. 2004; 14(22):5543-6. DOI: 10.1016/j.bmcl.2004.08.063. View

20.

Dixit M, Tripathi B, Tamrakar A, Srivastava A, Kumar B, Goel A . Synthesis of benzofuran scaffold-based potential PTP-1B inhibitors. Bioorg Med Chem. 2006; 15(2):727-34. DOI: 10.1016/j.bmc.2006.10.053. View